Source-grounded facts extracted from BRAINSTORM CELL THERAPEUTICS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Menghisteab Bairu was elected as Director at BRAINSTORM CELL THERAPEUTICS INC..
“the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) increased the size of the Board by one member and elected Dr. Menghisteab Bairu to serve as a member of the Board, effective October 28, 2021.”
Alla Patlis was appointed as Interim Chief Financial Officer at BRAINSTORM CELL THERAPEUTICS INC..
“The Board of Directors of the Company has appointed Alla Patlis, the Company’s current Controller, as the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, effective upon Mr. Shah’s resignation if a permanent Chief Financial Officer is not appointed prior to that time.”
Preetam Shah resigned as Chief Financial Officer at BRAINSTORM CELL THERAPEUTICS INC..
“On August 20, 2021, Preetam Shah, the Chief Financial Officer (and principal financial and accounting officer) of Brainstorm Cell Therapeutics Inc. (the “Company”), provided the Company with notice of his intent to resign from the Company, effective August 31, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.